Uluru Inc. (fka ULUR)

[alexander77]

Revenues were $466,864 for the six months ended June 30, 2010, as compared to revenues of $304,823 for the six months ended
June 30, 2009, and were comprised of licensing fees of approximately $100,000 for a Zindaclin® milestone and $46,000 for two OraDisc™ licensing agreements, $75,000 of foreign royalties from the sale of Zindaclin® by our distributor, $34,000 of domestic royalties from the sale of Aphthasol® by our distributor, and product sales of approximately $138,000 for Aphthasol® and $74,000 for Altrazeal®.

The six months ended June 30, 2010 revenues represent an overall increase of approximately $162,000 versus the comparative six
months ended June 30, 2009 revenues, due primarily to an increase of $138,000 in Aphthasol® product sales as we did not sell
any Aphthasol® finished product to our domestic distributor during the first quarter of 2009 and an increase of $100,000 in
licensing due to the achievement of a Zindaclin® milestone. These increases were partially offset by decreases in Zindaclin®
royalty fees of $25,000 and sponsored research of $32,000.


"Net cash provided by investing activities during the six months ended June 30, 2010 was $300,000 and relates to the proceeds
received in June 2010 from the divestiture of our Zindaclin® intangible asset. The Company expects to receive additional
payments from the divestiture of Zindaclin® of $250,000 by November 2010, $250,000 in June 2011, and $250,000 in June 2012."

http://www.otcmarkets.com/edgar/GetFilingPdf?FilingID=7417336